COVER STORY
The Cancer Pill Not Taken Costs Insurers in Long Run
As oral chemotherapy becomes more common, so does nonadherence. Cost is only one of the reasons.
The push to integrate health care services and financing may portend a move away from behavioral health carve-outs
Research says PA can help make treatments safer and more cost-effective, but data sharing must improve
Even today, studies show, only half of treatments are truly based on evidence. Here’s an organization looking to better that share, and it may behoove health plans to help.
When a respected provider organization took a stand against the costly new cancer drug, it was both surprising and encouraging
LEGISLATION & REGULATION
While local governments ponder just what course to take, health plans prepare to grab as much market share as possible
MEDICATION MANAGEMENT
Case management, prior authorization, and drug utilization control are required
THE FORMULARY FILES
EVIDENCE REVIEW
A summary of ECRI Institute’s Emerging Technology Evidence Report
TOMORROW’S MEDICINE
Devices that selectively destroy the renal nerves that affect hypertension have gained international approval, and availability in the United States is not far off
PLAN WATCH
The insurer’s tracking effort helps physicians keep tabs on patients who may not be taking their drugs correctly
MANAGED CARE OUTLOOK
NEWS & COMMENTARY
NEWS & COMMENTARY
NEWS & COMMENTARY
SNAPSHOT
NEWS & COMMENTARY
NEWS & COMMENTARY
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.